



Attorney Docket No.: A-67984/464334-00102/RFT/TAL/NBC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Chang *et al.*

Examiner: I. Fields

Group Art Unit: 1645

Serial No. 09/500,376

Filed: February 8, 2000

For: *Baculovirus
Produced
Plasmodium
Falciparum Vaccine*

CERTIFICATE OF MAILING
I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Box AF Assistant Commissioner for Patents, Washington, DC 20231.

Date: 10/2/02
Signed: *Jere Valles*
Jere Valles

#16
JM
10/16/02

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. §1.116

Box AF
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is in Response to the final Office Action mailed July 2, 2002 for the above-referenced U.S. Patent Application. The Commissioner is hereby authorized to charge any additional fees, including extension of time fees or other relief as may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our File A-67984/RFT/TAL/NBC).

RECEIVED
OCT 11 2002
TECH CENTER 1600/2900

REMARKS

Claims 37-55 are pending. An appendix of "Pending Claims 37-55" is attached for the Examiner's convenience.

Claim Rejections - 35 USC §112, First Paragraph

Claim 50 (and dependent claims 51-55) stand rejected under 35 U.S.C. §112, first paragraph as not being enabled by the specification. Specifically, the Examiner argues that